Developing a new method to produce safer and more efficient gene therapy DNA
Official title: Vectorless supercoiled DNA: a new scalable abacterial in vitro system to improve gene therapy safety and production efficiency
Funded at Chesapeake Genomic Systems LLC · NIH-10921447 · Data updated 2026-11-12
This study is exploring a new way to make supercoiled DNA without using bacteria, which could lead to safer and more effective gene therapies for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chesapeake Genomic Systems LLC NIH-funded |
| Lab location | 1 site (Halethorpe, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $295,924 |
| NIH project number | 1R41GM154562-01 |
| Project ID | NIH-10921447 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients requiring gene therapy for various genetic conditions or diseases.
✕Less likely to help
Patients who do not require gene therapy or have conditions unrelated to genetic modifications may not benefit from this research.
What this research studies
This research focuses on creating a novel, completely synthetic method for producing supercoiled DNA without the use of bacteria, which is a significant improvement over current methods that rely on bacterial plasmids. By utilizing a new technology called cyclic heteroduplex thermostable ligation assembly (CHTLA), the researchers aim to optimize the production of vectorless supercoiled DNAs. This approach could enhance the safety and efficiency of gene therapy by eliminating bacterial components that can cause immune responses. Patients may benefit from more effective and safer gene therapies as a result of this innovative production method.
Why it matters
Potential benefit: If successful, this research could lead to safer and more efficient gene therapies for patients.
How similar studies have gone: While the approach of using vectorless supercoiled DNA is innovative, similar technologies have shown promise in improving gene therapy production, indicating potential for success.
Where this research is happening
-
Chesapeake Genomic Systems LLC
Halethorpe, United States Active
Researchers
- Principal investigator: Bai, Haibo — Chesapeake Genomic Systems LLC
- Study coordinator: Bai, Haibo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.